Clinical trials
Unresectable Mucosal Melanoma clinical trials
Below are recruiting unresectable mucosal melanoma clinical trials, each written for real people, not researchers. We’re tracking 15 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05384496RecruitingPhase 2
Axitinib and nivolumab for advanced mucosal melanoma
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
Harrison, New YorkAges 18 years+ - NCT06466434RecruitingPhase 2
Prebiotic diet to boost immunotherapy for melanoma
This trial tests whether a special prebiotic diet can help your body's bacteria (microbiome) better respond to standard immunotherapy for advanced melanoma that cannot be removed by surgery. If you are starting your first immunotherapy, you may be able to join.
Houston, TexasAges 18 years+ - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT05428007RecruitingPhase 2
Sarilumab with three immunotherapy drugs for advanced melanoma
This Phase 2 trial tests whether adding sarilumab (an immune-blocking medicine) to three immunotherapy medicines can shrink unresectable, advanced melanoma that cannot be removed with surgery. It aims to improve how well the immune system controls the cancer, especially in Stage III or Stage IV disease.
Los Angeles, CaliforniaAges 18–100 - NCT07155317RecruitingPhase 2
Time-of-day immunotherapy for advanced melanoma
This trial tests whether giving immunotherapy at a specific time of day can improve its effectiveness for advanced melanoma that cannot be removed by surgery. It may help you if you have stage IV melanoma and have not had immunotherapy in the last year.
Atlanta, GeorgiaAges 18 years+ - NCT07076550RecruitingPhase 1
Radioactive drug for advanced melanoma
This trial tests a new radioactive drug (A9-3408) for people with advanced melanoma that has not responded to standard treatments. The drug is designed to target and destroy melanoma cells. The study is early phase, so it is mainly checking safety and how well the drug works.
Melbourne, VictoriaAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT07221734RecruitingPhase 3
Testing MB11 versus Opdivo for advanced melanoma
This trial compares a new drug, MB11, to the standard treatment Opdivo for people with advanced melanoma that hasn't been treated yet. The goal is to see if MB11 works just as well.
FunchalAges 18 years+ - NCT06624644RecruitingPhase 2/Phase 3
LNS8801 with or without pembrolizumab for advanced melanoma
This trial tests a new drug called LNS8801, alone or with pembrolizumab, for people with advanced melanoma that has stopped responding to prior treatments, especially anti-PD-1 therapy.
Newport Beach, CaliforniaAges 18 years+ - NCT05546827RecruitingPhase 2
Pre-surgery radiation plus immunotherapy for mucosal melanoma
This Phase 2 trial tests giving radiation and immunotherapy before surgery for mucosal melanoma in the nose/sinuses or rectum. It may help shrink the tumor and improve outcomes while aiming to control the disease locally and in nearby areas.
Houston, TexasAges 18 years+ - NCT06284590RecruitingPhase 2
Injected immunotherapy plus pembrolizumab for resistant melanoma
This study tests a new approach for advanced melanoma that is not responding to standard immunotherapy (like pembrolizumab). It combines a targeted injection directly into the tumor (L19IL2, L19TNF, or both) with pembrolizumab. The goal is to see if this combination can shrink tumors and help the immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT06797297RecruitingPhase 2
Study of IBI363 vs pembrolizumab for advanced mucosal or acral melanoma
This trial tests a new drug, IBI363, compared to the standard drug pembrolizumab (Keytruda) for people with advanced mucosal or acral melanoma who have not had treatment before. It aims to see if IBI363 works better or as well as the usual treatment.
Hefei, AnhuiAges 18 years+ - NCT06743126RecruitingPhase 3
IMA203 vs standard treatment for advanced skin cancer
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
Phoenix, ArizonaAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Phoenix, ArizonaAges 18 years+ - NCT07215988Recruiting
Studying insurance for skin cancer treatment
This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.
Columbus, OhioAges 18 years+
Hear when a new Unresectable Mucosal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable mucosal melanoma?
- Yes. Clin2 currently lists 15 recruiting unresectable mucosal melanoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable mucosal melanoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable mucosal melanoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.